secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001437749-23-005471
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica appoints Tanya Lewis to board; Burroughs resigns
----------------------------------------------------------

- Amy L. Burroughs resigned as director effective March 1, 2023; no disagreement with company.
- Tanya N. Lewis appointed to fill vacancy, effective March 1, 2023.
- Lewis is Chief Development Operations Officer at Replimune (Nasdaq:REPL) with 25+ years drug development experience.
- Lewis received option to purchase 26,443 shares at $1.77/share, vesting quarterly over 3 years.
- Company working to resolve clinical hold on ReMEDy2 AIS trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923005471/0001437749-23-005471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923005471/dmtp20230303_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-005471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer